Indian drugmakers are implementing a fundamental strategic transformation, reducing reliance on US generics while pivoting toward specialty medicines, biosimilars, and emerging markets to drive sustainable growth. According to reports from Business Standard, management commentary from major companies including Sun Pharmaceutical Industries, Dr Reddy's Laboratories, Cipla, and Lupin indicates this broader industry transition toward higher-value products and geographically diversified revenue streams. The challenge becomes particularly significant when companies move beyond simple tablets to complex products like injections, inhalers, skin patches, and topical creams, which are more difficult to develop and manufacture but offer better growth opportunities and are generally less crowded than traditional generic medicines. Government policy has provided crucial support through the Production Linked Incentive scheme, putting serious money into domestic API production - cutting dependence on imported raw materials and building a more stable supply chain from end to end.
Sun Pharma's Global Innovative Medicines business crossed $1.4 billion in 2025-26 (FY26) and now contributes more than 22 per cent of consolidated sales. As reported by Business Standard, Aalok Shanghvi, chief operating officer, highlighted that innovative medicines has been an important new driver for growth in emerging markets, with Ilumya performing well across several markets such as Romania, Brazil, and the partner market of China. The company's strategy reflects the sector's evolution from low-cost generic suppliers into globally diversified specialty pharma companies. Specialty segments like inhalation anesthetics — sevoflurane, for instance — sit right in the middle of this transformation, offering harder-to-produce products with smaller competitive fields and genuine global demand.
Dr Reddy's delivered the highest-ever annual revenues in FY26, demonstrating resilient operating performance despite product-specific headwinds and certain one-time impacts. According to Business Standard, M V Narasimham, chief financial officer, emphasized that the underlying base business continued to deliver double-digit growth for both the quarter and full year FY26. The company has built a diversified global pharmaceutical business by combining generics, APIs, biosimilars, and consumer healthcare across multiple markets, with its largest business segment being Global Generics. Dr Reddy's operates across the United States, India, Europe, and emerging markets, with generic medicines accounting for the majority of prescriptions filled in the country and the company maintaining a meaningful presence in Russia and several emerging markets to diversify its revenue base.
Cipla's African business continued to deliver market-leading growth and its EMs and Europe business operations scaled meaningfully to become a $400 million-plus business unit. As reported by Business Standard, Achin Gupta, managing director and global CEO, highlighted that these achievements demonstrate disciplined execution and commitment to sustainable and diversified growth across geographies. The company has identified South Africa, respiratory therapies, and branded prescription businesses as major growth drivers while expanding its presence across international markets. India remains one of the company's strongest markets, where doctors frequently prescribe medicines under specific brand names, even when the underlying molecule is off-patent, creating opportunities for companies that have built strong relationships with doctors and established trusted brands over time.
Lupin reported strong growth across India, emerging markets, and developed markets outside the US while investing in complex injectables, respiratory products, and biosimilars. According to Business Standard, Ramesh Swaminathan, executive director and global CFO, noted that the company's strategy of focusing on complex products has paid handsome dividends, citing launches such as Risperdal Consta, Glucagon, and Liraglutide. The company has a pipeline of more than 60 injectable and respiratory products under development and plans to launch its first biosimilars in the US during 2026-27, with Brazil emerging as a major growth market. Lupin's focus on complex products reflects the company's strategy of moving into higher-value product categories, with these products offering better growth opportunities and being generally less crowded than traditional generic medicines.
